Back to Archived News
SensiVida Medical Technologies Receives Notice of Allowance From US Patent and Trademark Office
Tuesday, February 22, 2011
Henrietta, NY -- SensiVida Medical Technologies, Inc. (PINKSHEETS: SVMT), a developer and provider of minimally invasive digital diagnostic technologies and devices, announced today that the company has received a notice of allowance from the U. S. Patent and Trademark Office for one of its key patent applications, titled "Minimally Invasive Allergy Testing System."
This patent is the first of the Company's intellectual property portfolio to receive such an allowance notice and is considered fundamental to current commercialization plans for its proprietary digital allergy system. The patent application discloses a number of aspects of the system design for the Company's first allergy test product, including the delivery of allergens using microneedle arrays and the detection of patient response using digital imaging.
The use of microneedles for allergen delivery is a painless alternative to the standard means used for the Skin Prick Test (SPT). The system allows for a wearable, compact, sensing device which decreases the skin test area for the patient and results in significantly less trauma to the skin. Claims allowed in this patent provide means to reduce test areas down to a few square inches; this is in contrast to the current practice of using large areas of the skin for the standard SPT that typically utilizes the patient's forearms or back. The Company anticipates that this design will also enable significant improvement in measurement variability, improve test productivity and will provide an overall better patient experience.
About SensiVida Medical Technologies, Inc.
SensiVida is a developer and provider of minimally invasive diagnostic devices with proprietary, microsystems-based technology that automates bio-sensing and data acquisition while minimizing patient discomfort. The Company's optical-digital platform technology addresses a number of multi-billion dollar market opportunities: allergy testing, pain-free automated glucose monitors, blood coagulation testing, TB testing, cholesterol monitoring, and more.
SensiVida has an exclusive worldwide license to nine pending patents. In addition to the SensiVida allergy test, the product pipeline, based on the same microsystem and image processing technology, includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient's test schedule, automatically recording the patient's glucose level without pain, bio-fouling or clogging. For more information about SensiVida, please visit www.sensividamedical.com.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Quarterly Report on Form 10Q and related 8-K filings.
Back to Archived News